-
Original Article
-
Korean J Med. 2009;76(2):179-185.
- 여성 폐암 환자에서 Gefitinib과 Erlotinib 치료 성적 비교
-
문대성 &#; 장태원 &#; 옥철호 &#; 정만홍 &#; 김도현 &#; 최인수, , , , ,
-
- Comparison of the therapeutic outcome between gefitinib and erlotinib in female patients with non-small-cell lung cancer
-
Dae Sung Moon, Tae Won Jang, Chul Ho Oak, Maan Hong Jung, Do Hyun Kim, In Soo Choi
-
-
- Abstract
- Background/Aims
Lung cancer is the leading cause of cancer death worldwide. There are significant gender differences
in lung cancer: most females with lung cancer are non-smokers and they are diagnosed with adenocarcinoma. Epidermal
growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are more effective in female lung cancer patients, but the
results
with gefitinib and erlotinib differ. This study compared the therapeutic response and toxicity of gefitinib and
erlotinib in female lung cancer patients.
Method: We retrospectively reviewed the clinical information on patients treated with gefitinib or erlotinib for more than
one month at Kosin University Gospel Hospital from February 2004 to November 2007.
Results
Forty-two patients (26 gefitinib vs. 16 erlotinib) were enrolled during this period. Their median age was 58
years. Thirty-six patients (85%) were non-smokers and 35 patients (83%) had adenocarcinoma. There were 24% at stage
IIIb and 76% at stage IV. The median survival time was 793 days. In the gefitinib group, 69% of the patients received
3rd-line chemotherapy, while 12 of 16 (87.5%) in the erlotinib group received 2nd-line chemotherapy. There were no
significant differences in the overall response rate (gefitinib 39% vs. erlotinib 31%, p=0.524), median survival time
(gefitinib 605 days vs. erlotinib 510 days, p=0.455), and time to progression (gefitinib 186 days vs. erlotinib 262 days,
p=0.660). Rashes were more common in the erlotinib group (73.3% vs. 27%, p<0.001).
Conclusions
There were no significant differences in the response rate, overall survival, and time to progression
between the two groups. Rashes were more common in the erlotinib group. (Korean J Med 76:179-185, 2009)
Keywords :Female, Non-small-cell lung cancer, Gefitinib, Erlotinib
